Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced today that it will present multiple studies on its novel cancer drug candidate NXP900 at the upcoming 2025 American Association for Cancer Research (AACR) Meeting, scheduled for April 25-30 in Chicago, Illinois.
The clinical-stage biopharmaceutical company will showcase five presentations highlighting NXP900's potential across various oncology applications, including data from its first-in-human Phase 1 trial and several preclinical studies demonstrating efficacy in resistant cancer models.
First-in-Human Clinical Trial Results
Among the presentations is the first human data from the Phase 1 trial of NXP900 in patients with advanced solid tumors. This presentation, scheduled for April 29th from 9:00 AM to 12:00 PM, will provide initial safety and efficacy findings from the ongoing dose-escalation study.
NXP900 represents a novel approach to cancer treatment as a selective inhibitor of the SRC Family of Kinases (SFK), particularly targeting SRC and YES1. What distinguishes this compound is its ability to inhibit both the catalytic and scaffolding functions of the SRC kinase, effectively shutting down the entire signaling pathway.
Overcoming Treatment Resistance in Lung Cancer
Two presentations will focus specifically on NXP900's potential in non-small cell lung cancer (NSCLC). One study demonstrates how the compound can overcome resistance to osimertinib, a commonly used targeted therapy for EGFR-mutated NSCLC. A separate presentation will showcase NXP900's synergistic effects when combined with ALK inhibitors in resistant NSCLC models.
Dr. Ron Bentsur, Chairman, Chief Executive Officer and President of Nuvectis, commented, "These presentations represent significant progress in our NXP900 development program. The data suggest potential applications across multiple cancer types, particularly in addressing the critical challenge of treatment resistance."
Novel Mechanisms in Cancer Signaling
Additional research to be presented includes NXP900's ability to block YAP1 signaling in NSCLC cell lines. YAP1 is a transcriptional regulator involved in cell proliferation and has been implicated in cancer development and progression.
Perhaps most intriguing is the late-breaking research showing that endocrine therapy-resistant luminal A breast cancer cell lines demonstrate sensitivity to NXP900. This finding opens potential new treatment avenues for patients with hormone receptor-positive breast cancers that have developed resistance to standard therapies.
Comprehensive Development Program
NXP900 is one of two clinical-stage drug candidates in Nuvectis' pipeline. The company is also developing NXP800, an oral small molecule GCN2 activator currently in Phase 1b clinical trials for platinum-resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored trial for cholangiocarcinoma.
"Our focus remains on developing innovative precision medicines for serious oncology conditions with high unmet medical needs," added Dr. Bentsur. "The breadth of data being presented at AACR reflects our commitment to thoroughly understanding NXP900's mechanism of action and potential clinical applications."
Presentation Schedule
All NXP900 presentations are scheduled for April 29th, with sessions covering:
- First-in-human Phase 1 trial results (9:00 AM - 12:00 PM)
- Overcoming osimertinib resistance in NSCLC (2:00 PM - 5:00 PM)
- Synergy with ALK inhibitors in resistant NSCLC models (2:00 PM - 5:00 PM)
- Inhibition of YAP1 signaling in NSCLC cell lines (2:00 PM - 5:00 PM)
- Activity in endocrine therapy-resistant breast cancer (9:00 AM - 12:00 PM)
The company anticipates that data from these presentations will inform the planned expansion of NXP900 into Phase 1b studies, targeting specific cancer types where the drug has shown the most promising activity.
Clinical Development Outlook
Nuvectis is currently completing the Phase 1a dose-escalation study for NXP900, which aims to establish the recommended Phase 2 dose while assessing safety and preliminary efficacy signals. The company has indicated that the transition to Phase 1b expansion cohorts will follow the completion of this initial study.
Industry analysts note that novel kinase inhibitors with the ability to overcome resistance mechanisms represent a significant area of interest in oncology drug development. NXP900's unique dual inhibition of both catalytic and scaffolding functions potentially addresses limitations seen with previous generations of SRC inhibitors.
The 2025 AACR Meeting represents a significant opportunity for Nuvectis to showcase its progress to the scientific and investment communities as the company advances its precision oncology pipeline.
